Company news

Xenon Pharmaceuticals Inc. news in 2021

Xenon Pharmaceuticals Inc.'s news releases, calls and decks from 2021, newest first.

View company

Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2021)

December 2, 2021

Xenon Pharmaceuticals Presents Additional Positive Data from Phase 2b ‘X-TOLE’ Clinical Trial at the Annual Meeting of the American Epilepsy Society (AES 2021)

December 2, 2021

Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 9, 2021

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update

November 2, 2021

Xenon Pharmaceuticals Announces Closing of $345 Million Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

October 7, 2021

Xenon Pharmaceuticals Announces Pricing of $300.0 Million Public Offering

October 4, 2021

Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy

October 3, 2021

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101

October 2, 2021

Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone

September 7, 2021

Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Dr. Christopher Kenney as Chief Medical Officer

August 22, 2021

Xenon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 10, 2021

Xenon Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference

August 9, 2021

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Corporate Update

August 3, 2021

Xenon Pharmaceuticals to Participate at the William Blair Biotech Focus Conference 2021

July 12, 2021

Xenon Pharmaceuticals Announces Completion of Patient Randomization in XEN1101 Phase 2b “X-TOLE” Clinical Trial and Announces Upcoming Investor Webinar with Leading Epilepsy Key Opinion Leaders

July 6, 2021

Xenon Pharmaceuticals Provides Corporate Update Following its Annual Meeting of Shareholders

June 2, 2021

Xenon Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference

May 30, 2021

Xenon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 10, 2021

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2021 Financial Results and Provide Corporate Update

May 3, 2021

Xenon Pharmaceuticals to Participate in the Stifel 3rd Annual CNS Day

March 28, 2021

Xenon Pharmaceuticals Announces Closing of $115 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

March 11, 2021

Xenon Pharmaceuticals Announces Pricing of $100.0 Million Public Offering

March 8, 2021

Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares

March 8, 2021

Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder (MDD)

March 7, 2021

Xenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate Update

February 28, 2021

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2020 Financial Results

February 22, 2021

Xenon Pharmaceuticals Announces Promising New Pre-Clinical Data and Provides Clinical Overview of its XEN1101 Program at ASENT 2021

February 21, 2021

Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021

January 13, 2021

Calls in 2021